IP Library Granted Patent US 8,148,340
Granted Patent B2
US 8,148,340 · App. 10/888,089 · Granted Apr 3, 2012

Immunomodulatory oligonucleotides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,148,340
App. No.
10/888,089
Granted
Apr 3, 2012
Kind
B2
Abstract

Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.

Claims (7)

1. A method of increasing interferon-gamma in a subject comprising administering to a subject an immunostimulatory oligonucleotide/ delivery complex, said complex comprising an immunostimulatory oligonucleotide linked to a biodegradable delivery complex, wherein the immunostimulatory oligonucleotide is 8 to 40 nucleotides in length, has greater than two unmethylated cytosine-guanine dinucleotides and comprises 5′ X 1 X 2 CGX 3 X 4 3′, wherein C and G are unmethylated and X 1 , X 2 are nucleotides, and X 3 and X 4 are pyrimidines, in an amount sufficient to increase interferon-gamma in said subject.

2. The method of claim 1 , wherein said delivery complex is a liquid phase microcarrier.

3. The method of claim 1 , wherein said immunostimulatory oligonucleotide is covalently linked to said delivery complex.

4. The method of claim 1 , wherein said immunostimulatory oligonucleotide is non-covalently linked to said delivery complex.

5. The method of claim 1 , wherein said immunostimulatory oligonucleotide comprises a phosphate backbone modification.

6. The method of claim 5 , wherein said phosphate backbone modification is a phosphorothioate.

7. The method of claim 1 , wherein the immunostimulatory oligonucleotide does not include a GCG trinucleotide at a 5′ and/or 3′ terminal.

Assignments (6)
CONFIRMATORY LICENSE Recorded Oct 10, 2008
From: UNIVERSITY OF IOWA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021668/0538 →
CORRECTIVE TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED AT REEL 015219 FRAME 0865. (ASSIGNMENT OF ASSIGNOR'S INTEREST) Recorded Oct 7, 2004
From: KRIEG, ARTHUR M.
To: IOWA RESEARCH FOUNDATION, UNIVERSITY OF
Reel/Frame 015228/0314 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2004
From: KLINMAN, DENNIS
To: HEALTH AND HUMAN SERVICES, UNITED STATES OF AMERICA, THE, AS REPRESENTED BY THE SECRETARY
Reel/Frame 015219/0841 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2004
From: KRIEG, ARTHUR M.
To: IOWA, UNIVERSITY RESEARCH FOUNDATION OF
Reel/Frame 015219/0865 →
AGREEMENT Recorded Oct 5, 2004
From: STEINBERG, ALFRED D.
To: CPG IMMUNOPHARMACEUTICALS, INC.
Reel/Frame 015219/0882 →
CHANGE OF NAME Recorded Oct 5, 2004
From: CPG IMMUNOPHARMACEUTICALS, INC.
To: COLEY PHARMACEUTICAL GROUP, INC.
Reel/Frame 015219/0891 →